OncoTherapy Science (TSE:4564) General and Admin. Expense: 円289.4 Mil (TTM As of Mar. 2026)


TSE:4564 OncoTherapy Science Inc TSE:4564
50 GF Score
Price 円21.00
GF Value 円17.03
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is OncoTherapy Science General and Admin. Expense?

OncoTherapy Science TSE:4564 +5.00% 50 General and Admin. Expense is 円289.4 Mil as of Mar. 2026. GuruFocus rates TSE:4564 with a GF Score™ of 50/100 and a GF Value™ of 円17.03 (Modestly Overvalued). The stock has 1 warning sign investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. OncoTherapy Science's General and Admin. Expense for the six months ended in Mar. 2026 was 円71.4 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was 円289.4 Mil.

OncoTherapy Science General and Admin. Expense Related Terms

OncoTherapy Science General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for OncoTherapy Science's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science General and Admin. Expense Chart

OncoTherapy Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 436.28 431.64 265.03 294.07 289.41

OncoTherapy Science Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.43 204.29 89.78 218.02 71.39
TSE:4564
50GF Score
OncoTherapy Science Inc TSE:4564
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoTherapy Science General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円289.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of 円289.4 Mil mean?
OncoTherapy Science (TSE:4564) has a General and Admin. Expense of 円289.4 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on OncoTherapy Science and its competitors.
Is OncoTherapy Science's General and Admin. Expense too high?
OncoTherapy Science's current General and Admin. Expense is 円289.4 Mil. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's General and Admin. Expense compare to VRTX and REGN?
OncoTherapy Science's General and Admin. Expense of 円289.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on OncoTherapy Science and its competitors. OncoTherapy Science's current General and Admin. Expense is 円289.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円17.03, compared to a current price of 円21.00 — trading 23.3% above its estimated fair value. The current General and Admin. Expense is 円289.4 Mil. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current General and Admin. Expense is 円289.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoTherapy Science (TSE:4564) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued. The current stock price of 円21.00 is trading 23.3% above its estimated GF Value™ of 円17.03. GuruFocus considers OncoTherapy Science to be Modestly Overvalued.

Key valuation signals for TSE:4564:

  • General and Admin. Expense: 円289.4 Mil
  • GF Value™: 円17.03 vs. price of 円21.00 (23.3% above fair value)
  • GF Score™: 50/100 with 1 warning sign

No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OncoTherapy Science Business Description

Other Exchanges 30O:Germany
Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score

Get the complete analysis for TSE:4564

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円21.00
Price
円17.03
GF Value